<DOC>
	<DOCNO>NCT00393107</DOCNO>
	<brief_summary>Purpose study ass safety profile anti-lymphoma activity FC+R combination .</brief_summary>
	<brief_title>Safety Efficacy Fludarabine Cyclophosphamide + Rituximab</brief_title>
	<detailed_description>The natural history follicular lymphoma characterize high initial response rate chemotherapy follow invariably relapse , subsequent remission progressively short duration . The majority patient eventually die disease . As yet , gold standard treatment newly diagnose relapse advanced FL.Rituximab ( R ) show highly effective agent treatment FL , either alone combination chemotherapy . The ability R sensitize indolent lymphoma derive cell line cytotoxic chemotherapy agent demonstrate . Furthermore , fludarabine ( F ) may also sensitize cell effect R. Cyclophosphamide ( C ) F show vivo synergistic activity . In view single agent activity demonstrate synergy C F , F R , evaluate FC+R previously treat patient advanced FL . The primary aim study assess safety profile clinical activity FC+R combination . The secondary goal evaluate ability treatment convert bone marrow Bcl2 positivity patient achieve molecular remission .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>histologically document WHO grade 12 , CD20+ , follicular lymphoma relapse Follicular lymphoma stage III IV disease Stage II patient eligible present B symptom bulky disease need therapy opinion treat clinician measurable disease expect survival 6 month age 18 70 year undergone &lt; 3 line chemotherapy performance status 0 2 know HIV infection Known Hepatitis B C CNS lymphoma previous malignancy , cardiac , renal , hepatic , respiratory failure Pregnant lactating woman patient child bear potential unless use birth control measure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2006</verification_date>
	<keyword>follicular lymphoma</keyword>
	<keyword>non-Hodgkin lymphoma</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Rituximab</keyword>
	<keyword>combination</keyword>
	<keyword>immuno-chemotherapy</keyword>
	<keyword>relapse</keyword>
</DOC>